Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Impact · against what's priced in

Amphastar is positioned for a meaningful revenue boost through its sole-generic status for Atrovent and the remediation of BAQSIMI pricing leaks. While the 2027 biosimilar pipeline offers long-term optionality, the immediate catalysts are the $40M annual Atrovent opportunity and the recovery of BAQSIMI margins starting in Q3.

AMPH+0.50

No priced-in read yet